Uncovering trajectories of satisfaction with injectable opioid agonist treatment for severe opioid use disorder

Thursday, 24 October, 2019 - 15:00 to 16:30
Guided poster tours room


Background: For people with severe opioid use disorder (OUD), injectable opioid agonist treatment (iOAT), with hydromorphone or diacetylmorphine, is a safe and effective alternative to oral opioid agonist treatment. There is an increasing interest in patient reported experience measures (PREMs) in the field of addiction; one such approach is to measure client’s satisfaction. However, few studies have examined changes in perceived iOAT satisfaction over time and possible patient-level predictors associated with these trajectories.

Methods: RUTH (Research on the Utilization of Therapeutic Hydromorphone) was a prospective cohort study of 135 participants with severe OUD receiving iOAT in North America’s first program. Daily clinical record and bi-monthly self-report measures were collected over an 18-month follow-up period regarding participant’s treatment engagement (daily adherence, medication received, dose) self-reported outcomes (substance use, health, quality of life), and perceived treatment experience (satisfaction, qualitative perceptions). The outcome of interest, perceived treatment satisfaction, was measured with the Client Satisfaction Questionnaire (CSQ-8). Item and total mean CSQ-8 scores were calculated and compared using Student’s t and Mann-Whitney U tests depending on variable distribution. A two-level hierarchical linear model examined individual change in CSQ-8 scores associated with time-varying (treatment engagement and self-reported outcome variables) and time-invariant (participant baseline characteristics).

Results: Data analysis is in progress.

Conclusions: To our knowledge, this study will be the first to explore trajectories of treatment satisfaction with iOAT and their potential relationship with patient-level characteristics. Such data deepen understanding of changes in treatment satisfaction over time and can be used to strengthen the responsiveness of iOAT for people with severe OUD.





Part of session